N3期头颈部鳞状细胞癌患者的临床结局:美国国家癌症数据库分析
该研究基于美国国家癌症数据库(NCDB)回顾性分析4867例接受原发手术或放化疗的N3期头颈部鳞状细胞癌患者。
要点
- N3期头颈鳞癌的治疗以放化疗为主。
- 非口咽原发N3患者5年总生存接近30%,与初始治疗方式无关。
- 口咽原发N3患者手术结局更优,主要受HPV阴性亚组影响。
核心结论
- N3期头颈部鳞状细胞癌的管理主要依赖放化疗。
- 非口咽原发N3患者5年总生存接近30%,与初始治疗方式无关。
- 口咽原发N3患者手术结局更优,主要受HPV阴性亚组影响。
研究设计与样本
- 回顾性分析美国国家癌症数据库(NCDB)中4867例接受原发手术或放化疗的N3期头颈部鳞状细胞癌患者。
关键数值与推荐
- 非口咽原发N3患者5年总生存接近30%,与初始治疗方式无关。
临床怎么用
- N3期头颈鳞癌可优先考虑放化疗,但口咽原发尤其HPV阴性患者应评估手术获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease. METHODS: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed. RESULTS: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Propensity-adjusted median survival was 54.2 and 44.8 months for surgery and CRT, respectively (P = .06). Oropharyngeal primary subsite demonstrated a survival advantage with surgery versus CRT with propensity-adjusted median survivals of 86.0 and 61.9 months, respectively (P < .05). CONCLUSION: Management of N3 HNSCC relies largely on CRT. Patients with N3 nodal disease with nonoropharyngeal primary tumors exhibit 5-year overall survival approaching 30% independent of initial treatment modality. Patients with oropharyngeal primaries exhibit improved outcomes with surgery largely influenced by the human papillomavirus (HPV)-negative subset. These data represent the most comprehensive analysis of N3 HNSCC outcomes and serves as a foundation for future research and clinical management.
引用
- Ko HC, Chen S, Wieland AM, et al. Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. Head Neck. 2017. PMID: 28737019. doi:10.1002/hed.24881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。